Institute cancer diagnostics spin-out secures £12.5 million

14M Genomics given £12.5M to develop cancer tests

Institute cancer diagnostics spin-out secures £12.5 million

141216-14mg1.pngPeter Campbell, Genome Research Limited
Cancer cells.

Wellcome Trust Sanger Institute spin-out company 14M Genomics (14MG) has received £12.5 million equity financing from Syncona Partners LLP (Syncona) to develop European clinical diagnostic and treatment decision services in cancer. 14MG is partnered with the Institute, to leverage the power of its state-of-the-art gene sequencing and cancer genome bioinformatics resources. The company will generate linked genomic and clinical datasets for major cancers, which will provide a reference base to enable diagnostic and prognostic stratification of patients, helping to guide treatment decisions for oncologists and patients.

"Our partnership with the Sanger Institute provides world-class resources that few start-up companies could access. This, and our relationship with Syncona, is proving a valuable gateway to access large clinical studies in cancer across Europe, at the scale and quality necessary to build medically useful clinical genomic datasets."

Andrew Sandham, Executive Chairman of 14MG

14MG was founded by the leaders of the Sanger Institute Cancer Genome Project, Professor Michael Stratton, Dr Peter Campbell and Dr Ultan McDermott. The company, based on the Wellcome Trust Genome Campus, is collaborating with European clinical partners in studies to generate linked clinical genomic datasets using cancer gene panel and other technologies. 14MG has licensed proprietary technology and bioinformatics software from the Sanger Institute and will capitalise on the Institute's research and clinical grade sequencing pipelines.

"The Cancer Genome Project has enabled us to make important discoveries in cancer gene biology. There is a real drive to introduce genomic medicine into healthcare, and the founding of 14MG aspires to realise the clinical utility of cancer genomics through services to oncologists and patients."

Professor Michael Stratton, co-founder of 14MG and Director of the Sanger Institute

The company's medical and bioinformatics teams are building a clinical genomic data resource with portal access appropriate for future clinical diagnostic services. Collaborations with leading academic centres are being established in haematological and solid tissue cancers, where there are strong indicators that cancer gene biology has prognostic and treatment guidance value. 14MG also intends to collaborate with pharmaceutical partners to provide clinical genomic services in the study of investigational drugs, informed by its cancer gene pathway discoveries.

"Syncona is a healthcare investment company that identifies and develops technologies with the potential of significantly impacting the healthcare market of the future. The development and commercialisation of cancer diagnostics requires deep and long term financial commitment and Syncona has the vision and resources to support companies like 14MG that will transform the diagnosis and treatment of cancer."

Martin Murphy, CEO of Syncona

Notes to Editors
Further information: 14M Genomics

Andrew Sandham: +44 (0) 1223 499975
Julia Wilson: +44 (0) 7818 430877

Selected Websites
Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Sanger Institute researcher, Henry Lee-Six, wins Dr Falk Pharma/Guts UK essay prize
Medical student working in the Cancer Genome Project wins prize for colon cancer research
2019 Chief Medical Officer’s Report published
Sanger Institute researchers contribute to Professor Dame Sally Davies' eleventh annual report
Multi-drug resistant malaria spreading in Asia
Study reveals importance of ongoing genomic surveillance for malaria control strategies